AIM ImmunoTech Reports Q3 2025 Financial Results

Aim Immunotech Inc. ( (AIM) ) has released its Q3 earnings. Here is a breakdown of the information Aim Immunotech Inc. presented to its investors.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. AIM ImmunoTech Inc. is a biopharmaceutical company focused on the research and development of therapeutics for treating cancers, viral diseases, and immune-deficiency disorders. The company is known for its flagship products, Ampligen and Alferon N Injection, which are being developed for various medical applications. In its latest earnings report for the third quarter of 2025, AIM ImmunoTech Inc. highlighted a net loss of $3.3 million, an improvement from the $3.7 million loss in the same period last year. The company also reported total revenues of $26,000, a decrease from $35,000 in the previous year, reflecting ongoing challenges in revenue generation. Key financial metrics from the report indicate a reduction in total liabilities to $11.6 million from $9.9 million at the end of 2024. The company also noted a significant decrease in operating expenses, with research and development costs dropping to $607,000 from $1.4 million, and general and administrative expenses falling to $1.8 million from $3.1 million in the previous year. AIM’s cash and cash equivalents increased to $2.3 million, up from $1.7 million at the end of 2024. Looking ahead, AIM ImmunoTech Inc. remains focused on advancing its clinical trials and exploring new therapeutic applications for Ampligen. The company’s management is optimistic about its strategic initiatives, although it continues to face challenges related to financial sustainability and regulatory compliance. AIM is actively working to improve its financial position and regain compliance with stock exchange listing requirements.